Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
Titel:
Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
Auteur:
Peffault de Latour, Regis Roeth, Alexander Kulasekararaj, Austin Scheinberg, Phillip Ueda, Yasutaka de Castro, Carlos M Di Bona, Eros Schrezenmeier, Hubert Langemeijer, Saskia MC Barcellini, Wilma Tavitian, Suzanne Panse, Jens Schafhausen, Philippe Mauad, Vitor AQ Kerloeguen, Cecile Levitch, Rafael Kumar, Rakesh Thorburn, Christine Maitra, Samopriyo Dahlke, Marion Risitano, Antonio M